Open AccessEffective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab
Author(s) -
Pınar Uysal,
Duygu Erge
Publication year - 2019
Publication title -
türk pediatri arşivi : i̇stanbul çocuk kliniği dergisi
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.237
H-Index - 11
ISSN - 1306-0015
DOI - 10.5152/turkpediatriars.2016.4042
Subject(s) - omalizumab , antihistamine , medicine , chronic urticaria , refractory (planetary science) , angioedema , dermatology , immunoglobulin e , immunology , antibody , physics , astrobiology
Omalizumab is a recombinant humanized monoclonal anti-IgE antibody. Until now, the efficiency of omalizumab in chronic spontaneous urticaria has been demonstrated in several studies. However in the literature, data showing the efficiency of omalizumab in different phenotypes of H1-antihistamine-refractory chronic urticaria are limited. In this report, the success of treatment with omalizumab from the first dose is presented in three patients with chronic spontaneous urticaria, chronic autoimmune urticaria, and idiopathic angioedema, who were unresponsive to high-dose H1-antihistamine. The symptoms of all patients resolved with the first dose of omalizumab and no symptom recurrence developed during the follow-up period. In this case presentation, the effective treatment of different phenotypes of H1-antihistamine-refractory chronic urticaria is discussed with a review of the literature.